No Slowdown: A Midyear Look At FDA Ad Enforcement, Law360

Partners Maarika Kimbrell and Jacqueline Berman were quoted in a Law360 article examining the US Food and Drug Administration's continued focus on prescription drug advertising enforcement during the first half of 2026.

Maarika and Jacqueline noted that the steady stream of enforcement letters demonstrates that last year's heightened scrutiny "was not a one-time effort and that FDA is putting significant sustained efforts behind ongoing enforcement." They also observed that, "Across all forms of promotion, FDA is also increasingly focused on whether the underlying studies support promotional statements, sometimes wading deep into the weeds of clinical trial conduct, design, and outcome," and concluded that companies should ensure promotional claims are fully supported by the underlying data and clinical studies.

Read the full Law360 article >>